Market Cap 9.52B
Revenue (ttm) 12.82B
Net Income (ttm) 936.34M
EPS (ttm) N/A
PE Ratio 13.62
Forward PE 12.19
Profit Margin 7.31%
Debt to Equity Ratio -95.97
Volume 481,600
Avg Vol 783,184
Day's Range N/A - N/A
Shares Out 71.50M
Stochastic %K 21%
Beta 1.13
Analysts Sell
Price Target $153.57

Company Profile

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative se...

Industry: Medical Care Facilities
Sector: Healthcare
Phone: 720-631-2100
Address:
2000 16th Street, Denver, United States
NVDAMillionaire
NVDAMillionaire Sep. 11 at 11:39 AM
$DVA Great piece that accurately captures DVA's current position. So if you want to refresh your understanding of DVA or learn about DVA for the first time, this is essential reading. https://beyondspx.com/quote/DVA/analysis/davita-s-resilient-core-dialysis-dominance-amidst-evolving-kidney-care-nyse-dva
0 · Reply
RRCORNER
RRCORNER Sep. 11 at 12:48 AM
$SIGY Sigyn vs. Statins: Better and Faster Sigyn Therapy™ dramatically outperforms statins: - Works in a single session versus weeks or months for statins. - Lowers both LDL-C and Lp(a), unlike statins. - Reduces inflammation and immediate MACE risk. - Safe and effective for statin-intolerant patients. $PFE $BMY $DVA
0 · Reply
WARRENBUFFETSIGNAL
WARRENBUFFETSIGNAL Sep. 9 at 7:22 PM
$CRMD $DVA $FMS BULLISH CORMEDIX
0 · Reply
Noname2022
Noname2022 Sep. 9 at 6:41 PM
$CRMD $FMS $DVA Great to have patient advocacy orgs backing a life saving preventive FDA approved Defencath for CVC’s Available at Fresenius but NOT Davita!
1 · Reply
Flexed1ga
Flexed1ga Sep. 9 at 1:39 PM
$DVA I’m a new investor in Davita and already I’ve blocked some folks . Love debate however don’t enjoy posts that are always negative and long. I’m a Davita patient thus buying the stock.
1 · Reply
StockAutoPro
StockAutoPro Sep. 8 at 3:03 PM
$DVA: Buy target $132.96 Sell target $141.71 Strong renal patient growth indicates potential upside for prominent dialysis services provider.
0 · Reply
iSayStupidStuff
iSayStupidStuff Sep. 6 at 5:47 AM
$DVA you going to buy it?
0 · Reply
Noname2022
Noname2022 Sep. 5 at 11:09 PM
$CRMD $DVA $FMS Fact: DefenCath cuts infections by 71%. It’s on formulary at Fresenius — not at DaVita.
2 · Reply
StockAutoPro
StockAutoPro Sep. 5 at 7:18 PM
$DVA: Buy target $135.42 Sell target $144.29 Strong quarterly earnings report indicates potential growth in leading kidney care provider. Consider investing.
0 · Reply
WARRENBUFFETSIGNAL
WARRENBUFFETSIGNAL Sep. 5 at 8:29 AM
$DVA DefenCath is saving lives. What are you waiting for to adopt it?
0 · Reply
Latest News on DVA
DaVita: Aggressive Buybacks Despite Rising Cost Of Debt

Aug 20, 2025, 9:36 AM EDT - 25 days ago

DaVita: Aggressive Buybacks Despite Rising Cost Of Debt


DaVita Inc. (DVA) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 10:02 PM EDT - 5 weeks ago

DaVita Inc. (DVA) Q2 2025 Earnings Call Transcript


DaVita Inc. 2nd Quarter 2025 Results

Aug 5, 2025, 4:05 PM EDT - 5 weeks ago

DaVita Inc. 2nd Quarter 2025 Results


DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call

Jul 17, 2025, 5:37 PM EDT - 2 months ago

DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call


DaVita: International Expansion And Buybacks Will Boost Returns

May 27, 2025, 11:30 AM EDT - 3 months ago

DaVita: International Expansion And Buybacks Will Boost Returns


DaVita Inc. Announces Offering of $750 Million Senior Notes

May 20, 2025, 8:51 AM EDT - 4 months ago

DaVita Inc. Announces Offering of $750 Million Senior Notes


DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript

May 12, 2025, 9:41 PM EDT - 4 months ago

DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript


DaVita First-Quarter 2025 Financial Results: Just the Numbers

May 12, 2025, 4:51 PM EDT - 4 months ago

DaVita First-Quarter 2025 Financial Results: Just the Numbers


DaVita Inc. 1st Quarter 2025 Results

May 12, 2025, 4:05 PM EDT - 4 months ago

DaVita Inc. 1st Quarter 2025 Results


DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

Apr 30, 2025, 11:00 AM EDT - 4 months ago

DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call


DaVita Says Ransomware Attack Affecting Some Operations

Apr 14, 2025, 7:35 AM EDT - 5 months ago

DaVita Says Ransomware Attack Affecting Some Operations


Dialysis firm DaVita hit by ransomware attack

Apr 14, 2025, 7:33 AM EDT - 5 months ago

Dialysis firm DaVita hit by ransomware attack


Berkshire Hathaway sells another 750,000 DaVita shares

Feb 19, 2025, 8:05 PM EST - 7 months ago

Berkshire Hathaway sells another 750,000 DaVita shares


DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 8:19 PM EST - 7 months ago

DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript


Berkshire sells some DaVita shares, cuts stake to 45%

Feb 13, 2025, 8:13 PM EST - 7 months ago

Berkshire sells some DaVita shares, cuts stake to 45%


DaVita forecasts 2025 profit below estimates, shares plummet

Feb 13, 2025, 6:07 PM EST - 7 months ago

DaVita forecasts 2025 profit below estimates, shares plummet


DaVita Inc. 4th Quarter 2024 Results

Feb 13, 2025, 4:05 PM EST - 7 months ago

DaVita Inc. 4th Quarter 2024 Results


DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call

Jan 30, 2025, 11:55 AM EST - 8 months ago

DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call


DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 9:27 PM EDT - 11 months ago

DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript


DaVita misses third-quarter profit estimates on higher costs

Oct 29, 2024, 4:23 PM EDT - 11 months ago

DaVita misses third-quarter profit estimates on higher costs


DaVita Inc. 3rd Quarter 2024 Results

Oct 29, 2024, 4:05 PM EDT - 11 months ago

DaVita Inc. 3rd Quarter 2024 Results


DaVita Appoints Jessica Hergenreter as Chief People Officer

Oct 17, 2024, 1:00 PM EDT - 11 months ago

DaVita Appoints Jessica Hergenreter as Chief People Officer


Drop Johnson & Johnson, Pick These Steady Eddie Stocks?

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Drop Johnson & Johnson, Pick These Steady Eddie Stocks?

DUK JNJ


NVDAMillionaire
NVDAMillionaire Sep. 11 at 11:39 AM
$DVA Great piece that accurately captures DVA's current position. So if you want to refresh your understanding of DVA or learn about DVA for the first time, this is essential reading. https://beyondspx.com/quote/DVA/analysis/davita-s-resilient-core-dialysis-dominance-amidst-evolving-kidney-care-nyse-dva
0 · Reply
RRCORNER
RRCORNER Sep. 11 at 12:48 AM
$SIGY Sigyn vs. Statins: Better and Faster Sigyn Therapy™ dramatically outperforms statins: - Works in a single session versus weeks or months for statins. - Lowers both LDL-C and Lp(a), unlike statins. - Reduces inflammation and immediate MACE risk. - Safe and effective for statin-intolerant patients. $PFE $BMY $DVA
0 · Reply
WARRENBUFFETSIGNAL
WARRENBUFFETSIGNAL Sep. 9 at 7:22 PM
$CRMD $DVA $FMS BULLISH CORMEDIX
0 · Reply
Noname2022
Noname2022 Sep. 9 at 6:41 PM
$CRMD $FMS $DVA Great to have patient advocacy orgs backing a life saving preventive FDA approved Defencath for CVC’s Available at Fresenius but NOT Davita!
1 · Reply
Flexed1ga
Flexed1ga Sep. 9 at 1:39 PM
$DVA I’m a new investor in Davita and already I’ve blocked some folks . Love debate however don’t enjoy posts that are always negative and long. I’m a Davita patient thus buying the stock.
1 · Reply
StockAutoPro
StockAutoPro Sep. 8 at 3:03 PM
$DVA: Buy target $132.96 Sell target $141.71 Strong renal patient growth indicates potential upside for prominent dialysis services provider.
0 · Reply
iSayStupidStuff
iSayStupidStuff Sep. 6 at 5:47 AM
$DVA you going to buy it?
0 · Reply
Noname2022
Noname2022 Sep. 5 at 11:09 PM
$CRMD $DVA $FMS Fact: DefenCath cuts infections by 71%. It’s on formulary at Fresenius — not at DaVita.
2 · Reply
StockAutoPro
StockAutoPro Sep. 5 at 7:18 PM
$DVA: Buy target $135.42 Sell target $144.29 Strong quarterly earnings report indicates potential growth in leading kidney care provider. Consider investing.
0 · Reply
WARRENBUFFETSIGNAL
WARRENBUFFETSIGNAL Sep. 5 at 8:29 AM
$DVA DefenCath is saving lives. What are you waiting for to adopt it?
0 · Reply
Noname2022
Noname2022 Sep. 5 at 1:24 AM
$CRMD $FMS $DVA https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-4/the-clinical-value-and-cost-effectiveness-of-defencath-for-reducing-catheter-related-bloodstream-infections-in-adult-patients-receiving-hemodialysis-through-a-central-venous-catheter
0 · Reply
Noname2022
Noname2022 Sep. 4 at 1:52 PM
$CRMD $DVA $FMS https://www.tandfonline.com/doi/abs/10.1080/17460913.2025.2547498
0 · Reply
Flexed1ga
Flexed1ga Sep. 4 at 11:53 AM
$DVA New investor here. Have been on dialysis for a year and figured I should own stock in this company as it’s part of my life now. The facility I attend has grown busier and busier.
0 · Reply
Noname2022
Noname2022 Sep. 3 at 6:28 PM
$CRMD $DVA A dialysis patient org supporting per patient billing for post tdapa to avoid a windfall to Davita for not adopting defencath https://www.dialysispatients.org/wp-content/uploads/2025/08/2025-DPC-Comment-Letter-ESRD-Prospective-Payment-System.pdf
3 · Reply
Flexed1ga
Flexed1ga Sep. 2 at 11:33 AM
$DVA Im a patient at Davita for almost a year. I'm a fairly large investor however don't own DVA. Few things that have kept me out are the CEO (a bit eccentric for me, data breaches, last month entire computer system went down for days, they have Iong term staff however can't hold younger new. Staffs over worked, patient care at time suffers. Hard time attracting young techs and nurses. They increased amount of patients however not staff. Being a patient I truly love the staff, however I pay attention to upper leadership down and how it effects patients. I'm going to say there sales are probably going to rise ( Ive not studied financials as the thought of buying in occurred today during treatment?. Obviously what I see and take in being a patient doesn't provide me a complete picture but does give me in site into the facility operations.
0 · Reply
Noname2022
Noname2022 Aug. 31 at 9:11 AM
$CRMD $FMS $DVA Just a reminder…
0 · Reply
Noname2022
Noname2022 Aug. 29 at 12:54 PM
$CRMD $FMS $DVA Life saving medication available at Fresenius ***Not at Davita***
2 · Reply
Noname2022
Noname2022 Aug. 26 at 10:53 PM
$CRMD $DVA non stop posting about patient safety but still don’t support Defencath preventative for the 2nd leading cause of death for dialysis patients, CBRSIs
StockAutoPro
StockAutoPro Aug. 26 at 8:20 PM
$DVA: Buy target $136.06 Sell target $144.96 Strong growth potential observed in leading kidney dialysis company due to increasing market demand.
0 · Reply
Yamauchii
Yamauchii Aug. 24 at 9:22 AM
$AKBA $DVA The Vocal study is officially ON and DaVita/Akebia are recruiting from 17 locations. Probably there is a overlap between Vocal trial and Pilot locations, but the bullish news is lot of Nephros, Nurses, etc are putting hands on the products and they are starting to get familiar with it. Considering we are in mid Q3, I really think we could see good result in terms of revenue for Vafseo this quarter. But looking slightly far on the horizon, Q4 really have the chance to be a monster quarter.
2 · Reply
ExoticDerivativesMgmt
ExoticDerivativesMgmt Aug. 23 at 11:25 AM
$DVA DaVita Inc is facing dialysis reimbursement pressure and labor cost inflation
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 22 at 3:27 AM
DaVita Under Fire After Cyberattack Compromises 2.7 Million Patients’ Information $DVA https://stocktwits.com/news/equity/markets/da-vita-under-fire-after-cyberattack-compromises-2-7-million-patients-information/chsmo8aRdiC
0 · Reply